MX2023006638A - Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel. - Google Patents
Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel.Info
- Publication number
- MX2023006638A MX2023006638A MX2023006638A MX2023006638A MX2023006638A MX 2023006638 A MX2023006638 A MX 2023006638A MX 2023006638 A MX2023006638 A MX 2023006638A MX 2023006638 A MX2023006638 A MX 2023006638A MX 2023006638 A MX2023006638 A MX 2023006638A
- Authority
- MX
- Mexico
- Prior art keywords
- vitamin
- analog
- skin diseases
- jak inhibitor
- treatment
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title abstract 2
- 229940046008 vitamin d Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 208000001052 Pachyonychia Congenita Diseases 0.000 abstract 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 206010047642 Vitiligo Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 abstract 1
- 208000007150 epidermolysis bullosa simplex Diseases 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 206010021198 ichthyosis Diseases 0.000 abstract 1
- 208000029443 keratinization disease Diseases 0.000 abstract 1
- 201000011486 lichen planus Diseases 0.000 abstract 1
- 201000005962 mycosis fungoides Diseases 0.000 abstract 1
- 201000008743 palmoplantar keratosis Diseases 0.000 abstract 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 abstract 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000002574 reactive arthritis Diseases 0.000 abstract 1
- 206010048905 steatocystoma multiplex Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al tratamiento tópico de enfermedades de la piel, tales como psoriasis, dermatitis atópica, alopecia, vitiligo, síndrome de Reiter, pitiriasis rubra pilaris, epidermólisis ampollosa simple, queratodermia palmoplantar, paquioniquia congénita, esteatocistoma múltiple, liquen plano cutáneo, linfoma cutáneo de linfocitos T, hidradenitis supurativa, dermatitis de contacto, ictiosis y un trastorno de queratinización, a través de (a) un inhibidor de JAK o una sal farmacéuticamente aceptable de este y (b) vitamina D3, un análogo de la vitamina D3 o una sal farmacéuticamente aceptable de esta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121531P | 2020-12-04 | 2020-12-04 | |
| US202163199876P | 2021-01-29 | 2021-01-29 | |
| PCT/US2021/061744 WO2022120131A1 (en) | 2020-12-04 | 2021-12-03 | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006638A true MX2023006638A (es) | 2023-08-22 |
Family
ID=80112060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006638A MX2023006638A (es) | 2020-12-04 | 2021-12-03 | Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4255442A1 (es) |
| JP (1) | JP2023552424A (es) |
| KR (1) | KR20230128472A (es) |
| AU (1) | AU2021390533A1 (es) |
| CA (1) | CA3204186A1 (es) |
| IL (1) | IL303410A (es) |
| MX (1) | MX2023006638A (es) |
| TW (1) | TW202237125A (es) |
| WO (1) | WO2022120131A1 (es) |
| ZA (1) | ZA202306521B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023057999A1 (en) * | 2021-10-08 | 2023-04-13 | Eptiva Therapeutics Ltd. | Calcitriol or calcitriol analogues for treating peripheral neuropathic pain disorders |
| WO2023102559A1 (en) * | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| BR112015003153A2 (pt) | 2012-08-17 | 2017-07-04 | Concert Pharmaceuticals Inc | baricitinib deuterado |
| EP2895172B1 (en) * | 2012-09-12 | 2019-02-06 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
| NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
| DK3786162T3 (da) | 2013-05-17 | 2023-10-09 | Incyte Holdings Corp | Bipyrazolderivater som jak-inhibitorer |
| TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備ｊａｋ１抑制劑之方法及其新形式 |
| MA52655A (fr) * | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
-
2021
- 2021-12-03 MX MX2023006638A patent/MX2023006638A/es unknown
- 2021-12-03 WO PCT/US2021/061744 patent/WO2022120131A1/en active Application Filing
- 2021-12-03 EP EP21841055.3A patent/EP4255442A1/en active Pending
- 2021-12-03 CA CA3204186A patent/CA3204186A1/en active Pending
- 2021-12-03 TW TW110145263A patent/TW202237125A/zh unknown
- 2021-12-03 JP JP2023534186A patent/JP2023552424A/ja active Pending
- 2021-12-03 AU AU2021390533A patent/AU2021390533A1/en active Pending
- 2021-12-03 KR KR1020237022418A patent/KR20230128472A/ko unknown
- 2021-12-03 IL IL303410A patent/IL303410A/en unknown
-
2023
- 2023-06-23 ZA ZA2023/06521A patent/ZA202306521B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230128472A (ko) | 2023-09-05 |
| EP4255442A1 (en) | 2023-10-11 |
| WO2022120131A1 (en) | 2022-06-09 |
| CA3204186A1 (en) | 2022-06-09 |
| AU2021390533A1 (en) | 2023-06-29 |
| US20220202834A1 (en) | 2022-06-30 |
| TW202237125A (zh) | 2022-10-01 |
| JP2023552424A (ja) | 2023-12-15 |
| ZA202306521B (en) | 2024-04-24 |
| IL303410A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202306521B (en) | Jak inhibitor with a vitamin d analog for treatment of skin diseases | |
| AU2002366280A1 (en) | Skin/hair equivalent with reconstructed papillae | |
| ES2129013B1 (es) | Utilizacion de la vitamina c o de sus derivados o analogos para estimular la sintesis de la elastina cutanea. | |
| GB2420559B (en) | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | |
| HK1109070A1 (en) | Treatment articles capable of conforming to an underlying shape | |
| WO2017182885A3 (en) | Compositions for the treatment of hyperkeratosis disorders | |
| WO2017155232A3 (ko) | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| EP2144608A4 (en) | SUN PROTECTION COMPOSITIONS AND METHODS | |
| NZ594184A (en) | Skin treatment | |
| EP1911494A3 (fr) | Utilisation d'oligosaccharides pour stimuler la production de beta-endorphine | |
| DE60314722D1 (de) | Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall | |
| NZ759173A (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
| TWI264312B (en) | Highly flexible transdermal therapeutic system with nicotine as active ingredient | |
| MX2023006754A (es) | Composiciones que comprenden polimeros naturales y uno o mas (bio)-alcanodioles. | |
| NZ767378A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| MX2023006729A (es) | Composiciones que comprenden filtros uv y uno o mas (bio)-alcanodioles. | |
| IL299038A (en) | IRAK joints and their uses | |
| DK0737069T3 (da) | Deuterede aktive stoffer til transdermal administrering | |
| AR124244A1 (es) | Inhibidor de jak con un análogo de la vitamina d para el tratamiento de enfermedades de la piel | |
| ATE363888T1 (de) | Verwendung von adenosin oder einem adenosinanalogen zur glättung von feinen linien | |
| HK1037135A1 (en) | Non therapeutic use of n-acetylglucosamine as skin exfoliant | |
| ES2191365T3 (es) | Utilizacion de acido carbonico para estabilizar o aumentar el regimen de sintesis de ceramidas en la epidermis. | |
| WO2022082071A8 (en) | Small molecule modulators of gp130 signaling pathways, topical formulations and method of use thereof | |
| MX2021011999A (es) | Sulfato de dextrano para afecciones inflamatorias de la piel. |